Talis Biomedical Corporation
TLIS · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $14 | $12 | $91 | $121 |
| - Cash | $77 | $130 | $233 | $138 |
| + Debt | $20 | $34 | $14 | $1 |
| Enterprise Value | -$44 | -$85 | -$128 | -$17 |
| Revenue | $0 | $4 | $0 | $11 |
| % Growth | -88.7% | – | -100% | – |
| Gross Profit | $0 | -$5 | -$3 | $10 |
| % Margin | 90% | -129.8% | – | 87.4% |
| EBITDA | -$66 | -$101 | -$189 | -$90 |
| % Margin | -16,030.3% | -2,776.9% | – | -820.6% |
| Net Income | -$62 | -$113 | -$190 | -$91 |
| % Margin | -15,050.2% | -3,094.5% | – | -832.7% |
| EPS Diluted | -34.12 | -63.65 | -126.13 | -314.06 |
| % Growth | 46.4% | 49.5% | 59.8% | – |
| Operating Cash Flow | -$53 | -$100 | -$171 | -$87 |
| Capital Expenditures | -$0 | -$2 | -$3 | -$8 |
| Free Cash Flow | -$54 | -$102 | -$174 | -$95 |